Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
List view / Grid view
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
Within this ebook, find articles examining the role of telomerase for universal cancer vaccines and discussing potential targets for neurodegenerative disease vaccines.
In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies.
This article delves into research at the University of California Los Angeles, US, where stem-cell derived brain organoids that can mimic electrical activity have been developed.
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
Researchers have turned human stem cells into brain cells to create a new model that can predict cognitive decline rate on an individualised level.
Scientists unveiled how a DNA repair protein may prevent Huntington’s disease, presenting a new target in future therapies.
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Fraser Owen about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.